(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.03%) $0.927
(0.21%) $10.86
(0.06%) $0.793
(-0.34%) $92.26
Live Chart Being Loaded With Signals
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally...
Stats | |
---|---|
Today's Volume | 8 600.00 |
Average Volume | 9 024.00 |
Market Cap | 127.69M |
EPS | $-0.170 ( 2024-03-14 ) |
Next earnings date | ( $-0.250 ) 2024-05-08 |
Last Dividend | $0.0500 ( 2023-04-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.45 |
ATR14 | $0 (0.00%) |
HLS THERAPEUTICS INC Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
HLS THERAPEUTICS INC Financials
Annual | 2023 |
Revenue: | $63.07M |
Gross Profit: | $55.45M (87.91 %) |
EPS: | $-0.850 |
Q4 | 2023 |
Revenue: | $15.86M |
Gross Profit: | $13.33M (84.03 %) |
EPS: | $0 |
Q3 | 2023 |
Revenue: | $16.04M |
Gross Profit: | $14.17M (88.34 %) |
EPS: | $-0.210 |
Q2 | 2023 |
Revenue: | $16.42M |
Gross Profit: | $14.64M (89.18 %) |
EPS: | $-0.290 |
Financial Reports:
No articles found.
HLS THERAPEUTICS INC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0500 | 2019-01-30 |
Last Dividend | $0.0500 | 2023-04-27 |
Next Dividend | $0 | N/A |
Payout Date | 2023-06-15 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $0.900 | -- |
Avg. Dividend % Per Year | 0.75% | -- |
Score | 2.81 | -- |
Div. Sustainability Score | 3.14 | |
Div.Growth Potential Score | 2.41 | |
Div. Directional Score | 2.78 | -- |
Year | Amount | Yield |
---|---|---|
2019 | $0.200 | 1.43% |
2020 | $0.200 | 0.81% |
2021 | $0.200 | 1.18% |
2022 | $0.200 | 1.36% |
2023 | $0.100 | 0.99% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
ZWC.TO | Dividend King | 2023-08-29 | Monthly | 8 | 4.07% | |
TRP.TO | Dividend King | 2023-09-28 | Quarterly | 30 | 3.81% | |
MFC.TO | Dividend King | 2023-08-22 | Quarterly | 25 | 3.24% | |
CUD.TO | Dividend Knight | 2023-09-25 | Monthly | 14 | 1.23% | |
XRE.TO | Dividend King | 2023-08-25 | Monthly | 23 | 2.24% | |
RCI-B.TO | Dividend Knight | 2023-09-07 | Quarterly | 25 | 1.93% | |
GEI.TO | Dividend King | 2023-09-28 | Quarterly | 13 | 3.90% | |
BASE.TO | Dividend King | 2023-08-30 | Monthly | 6 | 4.24% | |
VGV.TO | Dividend Knight | 2023-08-31 | Monthly | 7 | 1.42% | |
NBLY.TO | Dividend Junior | 2023-08-28 | Quarterly | 4 | 0.34% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.436 | 1.500 | -8.73 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.132 | 1.200 | -4.39 | -5.27 | [0 - 0.3] |
returnOnEquityTTM | -0.256 | 1.500 | -3.96 | -5.94 | [0.1 - 1] |
payoutRatioTTM | -0.0871 | -1.000 | -0.871 | 0.871 | [0 - 1] |
currentRatioTTM | 1.652 | 0.800 | 6.74 | 5.39 | [1 - 3] |
quickRatioTTM | 1.223 | 0.800 | 7.51 | 6.01 | [0.8 - 2.5] |
cashRatioTTM | 0.823 | 1.500 | 6.54 | 9.81 | [0.2 - 2] |
debtRatioTTM | 0.419 | -1.500 | 3.01 | -4.52 | [0 - 0.6] |
interestCoverageTTM | -1.143 | 1.000 | -1.534 | -1.534 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.489 | 2.00 | 9.84 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.486 | 2.00 | 9.76 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.897 | -1.500 | 6.41 | -9.62 | [0 - 2.5] |
grossProfitMarginTTM | 0.879 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.159 | 1.000 | -5.17 | -5.17 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.180 | 1.000 | -0.110 | -0.110 | [0.2 - 2] |
assetTurnoverTTM | 0.302 | 0.800 | -1.322 | -1.058 | [0.5 - 2] |
Total Score | 3.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.47 | 1.000 | -0.451 | 0 | [1 - 100] |
returnOnEquityTTM | -0.256 | 2.50 | -2.54 | -5.94 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.486 | 2.00 | 9.84 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.693 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.489 | 2.00 | 9.84 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.0871 | 1.500 | -0.871 | 0.871 | [0 - 1] |
pegRatioTTM | 0.102 | 1.500 | -2.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.250 | 1.000 | 6.24 | 0 | [0.1 - 0.5] |
Total Score | 2.41 |
HLS THERAPEUTICS INC
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators